Table 2 Dose to the OARs for different treatment techniques
From: Cerebral cortex dose sparing for glioblastoma patients: IMRT versus robust treatment planning
OAR | IMRT | IMRT with CS | Robust | Robust with CS |
|---|---|---|---|---|
TVa (D50) | 60.0 | 60.0 | 60.0 | 60.0 |
± 0.0 | ± 0.0 | ± 0.0 | ± 0.0 | |
Brainstem (D1) | 51.8 | 51.7 | 51.3 | 50.8 |
± 17.5 | ± 17.5 | ± 17.5 | ± 17.3 | |
Cerebellum (D50) | 15.5 | 15.2 | 14.3 | 14.3 |
± 17.1 | ± 17.4 | ± 17.3 | ± 17.5 | |
Cortex ipsib (D1) | 48.9 | 35.0 | 43.8 | 33.6 |
± 3.9 | ± 3.3 | ± 4.6 | ± 3.0 | |
Cortex contrab (D1) | 44.1 | 33.7 | 41.0 | 32.6 |
± 10.4 | ± 5.8 | ± 10.0 | ± 5.7 | |
Hemisphere ipsi (D50) | 37.4 | 32.5 | 34.2 | 30.7 |
± 23.1 | ± 20.5 | ± 22.8 | ± 20.3 | |
Hemisphere contra (D50) | 21.1 | 17.5 | 19.4 | 16.5 |
± 13.1 | ± 10.2 | ± 12.9 | ± 10.4 | |
Eye ipsi (D1) | 12.6 | 11.7 | 13.3 | 12.3 |
± 7.4 | ± 6.8 | ± 8.6 | ± 7.3 | |
Eye contra (D1) | 11.2 | 10.3 | 10.3 | 10.3 |
± 6.9 | ± 6.1 | ± 6.3 | ± 6.4 | |
Lens ipsi (D1) | 4.1 | 4.1 | 4.2 | 4.3 |
± 2.0 | ± 2.2 | ± 2.2 | ± 2.2 | |
Lens contra (D1) | 3.7 | 3.6 | 3.5 | 3.4 |
± 1.9 | ± 2.0 | ± 2.0 | ± 2.0 | |
Optic nerve ipsi (D1) | 36.1 | 33.5 | 34.8 | 31.7 |
± 21.0 | ± 19.9 | ± 20.1 | ± 18.8 | |
Optic nerve contra (D1) | 27.1 | 23.4 | 25.8 | 22.2 |
± 15.5 | ± 13.7 | ± 15.7 | ± 13.3 | |
Cochlea ipsi (D50) | 23.6 | 23.2 | 22.6 | 22.0 |
± 20.9 | ± 20.8 | ± 21.3 | ± 21.1 | |
Cochlea contra (D50) | 9.2 | 8.7 | 8.4 | 7.9 |
± 9.8 | ± 9.5 | ± 9.5 | ± 9.2 | |
Hippocampus ipsi (D50) | 43.0 | 41.4 | 41.5 | 40.4 |
± 22.3 | ± 22.6 | ± 22.5 | ± 22.5 | |
Hippocampus contra (D50) | 30.7 | 27.0 | 29.2 | 25.8 |
± 12.8 | ± 10.7 | ± 12.4 | ± 10.3 |